The importance of renin-angiotensin blockade in patients with cardio-renal disease.
The existence of the renin-angiotensin-aldosterone system was first postulated over 100 years ago. Following the identification of all the major components, came the discovery of their potential pathogenicity in cardiovascular and renal disease. The introduction of drugs that inhibit the synthesis or actions of this system has prompted a number of trials that have largely shaped how cardiovascular and renal disease is managed today. The continued discovery of yet more components of this system promises to further our understanding of its influence on disease processes and herald the development of more highly selective drugs, ensuring that the renin-angiotensin-aldosterone system will continue to be a key area of interest for many years to come.
Benavente
David
D
Department of Nephrology, Queen Elizabeth Hospital Birmingham, Birmingham B15 2TH, UK.
Chue
Colin D
CD
Ferro
Charles J
CJ
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000401:mortality / Q000451:nursing* / Q000503:physiopathology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000401:mortality / Q000451:nursing* / Q000503:physiopathology; D016032:Randomized Controlled Trials as Topic; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology; D015996:Survival Rate
D000806:Angiotensin-Converting Enzyme Inhibitors